InvestorsHub Logo
Followers 86
Posts 25803
Boards Moderated 0
Alias Born 09/15/2003

Re: None

Thursday, 03/23/2006 10:24:31 AM

Thursday, March 23, 2006 10:24:31 AM

Post# of 1036
Looking forward. I claim a nice 3rd quarter run (sept06), prior to earnings. Earnings are insignificant. As to earnings will be a cost saving announcement that coat-tails from the accepted graduation of the phase 1 trial from the FDA. oddly this company has already passed the three phase test for this study of its Parkinsons disease and the FDA has it doing it again. So America is dieing waiting for an imaging tool to help give a better grade of life to thousands. Keeping people hopefull, but generally ending up dieing before new testing developments are allowed on the general public.

Keep it under your accumulation list.

accumulate for that 3rd Q,based on this statement (IMPORTANT)(parkinsons/movement disease imaging tool)

I received a return call from the company yesterday. I actually have no questions. Just making sure someone had a real voice before I toy more of their playground. Just hearing the voice! Sincerity was instilled.

Nearly 3.3 million Americans age 19 and younger used an ADHD drug last year. The company is also in clinicals for ADHD

123 I-Based imaging agent for the objective diagnosis of Attention Deficit Hyperactivity Disorder (ADHD)
Phase II

The headlines tonight are all about ADHD drugs being softened for their labeling. These same headlines or similiar will return periodically. No one knows truely what to do.

New York Times article added to post


Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.